
Chronic Refractory Cough - Pipeline Insight, 2024
Description
Chronic Refractory Cough - Pipeline Insight, 2024
DelveInsight’s, “Chronic Refractory Cough - Pipeline Insight, 2024” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Chronic Refractory Cough pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Chronic Refractory Cough: Overview
Chronic refractory cough (CRC) is defined as a clinical condition in which the cause of the cough remains unclear after comprehensive examination and treatment, or the cause is clear but symptomatic treatment is ineffective. It is a persistent cough lasting more than eight weeks that fails to respond to standard treatments. This condition can be particularly challenging for patients and healthcare providers due to its elusive underlying causes and resistance to conventional therapies. Common etiologies such as asthma, gastroesophageal reflux disease (GERD), and postnasal drip are often ruled out, leaving a subset of patients without a clear diagnosis. This lack of identifiable cause necessitates a comprehensive and often multidisciplinary approach to management, which might include advanced diagnostic testing and evaluation by specialists in pulmonology, gastroenterology, and otolaryngology.
The impact of chronic refractory cough on patients' quality of life is significant, as it can lead to physical discomfort, psychological stress, and social embarrassment. Patients often experience fatigue, sleep disturbances, and even urinary incontinence due to the persistent nature of their cough. These symptoms can exacerbate anxiety and depression, creating a vicious cycle that further complicates management. The social implications are equally distressing, as persistent coughing can lead to social isolation and misunderstandings, especially in settings where a cough might be perceived as contagious.
Management strategies for CRC are often tailored to the individual patient and may include pharmacological and non-pharmacological interventions. Neuromodulatory treatments such as low-dose opioids, gabapentin, or amitriptyline have shown some promise in reducing cough reflex sensitivity. Additionally, speech therapy techniques, including cough suppression strategies and breathing exercises, can be beneficial. In some cases, lifestyle modifications, such as avoiding known cough triggers or optimizing treatment for underlying conditions, play a crucial role. Despite these interventions, treatment remains challenging, and ongoing research is crucial to develop more effective therapies for this debilitating condition.
""Chronic Refractory Cough- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Refractory Cough pipeline landscape is provided which includes the disease overview and Chronic Refractory Cough treatment guidelines. The assessment part of the report embraces, in depth Chronic Refractory Cough commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Refractory Cough collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Refractory Cough R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Refractory Cough.
This segment of the Chronic Refractory Cough report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic Refractory Cough Emerging Drugs
- GSK5464714: GSK
Further product details are provided in the report……..
Chronic Refractory Cough: Therapeutic Assessment
This segment of the report provides insights about the different Chronic Refractory Cough drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Chronic Refractory Cough
- There are approx. 4+ key companies which are developing the therapies for Chronic Refractory Cough. The companies which have their Chronic Refractory Cough drug candidates in the most advanced stage, i.e. Phase III include, GSK.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Chronic Refractory Cough: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Chronic Refractory Cough therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Refractory Cough drugs.
Chronic Refractory Cough Report Insights
- Chronic Refractory Cough Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Chronic Refractory Cough drugs?
- How many Chronic Refractory Cough drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Refractory Cough?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic Refractory Cough therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Chronic Refractory Cough and their status?
- What are the key designations that have been granted to the emerging drugs?
- GSK
- Trevi Therapeutics
- GSK5464714
- Nalbuphine ER
Key Players
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Chronic Refractory Cough: Overview
- Introduction
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Chronic Refractory Cough– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- GSK5464714: GSK
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Chronic Refractory Cough Key Companies
- Chronic Refractory Cough Key Products
- Chronic Refractory Cough- Unmet Needs
- Chronic Refractory Cough- Market Drivers and Barriers
- Chronic Refractory Cough- Future Perspectives and Conclusion
- Chronic Refractory Cough Analyst Views
- Chronic Refractory Cough Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.